Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow.

Already subscribed? Sign in now

Learn more about CME

Dabigatran for Thromboembolic Prophylaxis in Atrial Fibrillation: Evidence Profile

MoreVert
AddCircleOutlineFollow
ShareShare
AddCircleOutlineFollow
Follow
ShareShare
Share

You must be a subscriber to see the full topic content.

  • Related Summaries

  • Overview

  • Mechanism of Action

  • Efficacy for Embolic Stroke Prevention

  • Risks

  • Side Effects

  • Burden on Daily Life

  • Emergency Reversal

  • KeyboardArrowRight

    References

    • General references used

    • DynaMed Editorial Process

    • Special acknowledgements

Section Editor
Brian S. Alper MD, MSPH, FAAFP
KeyboardArrowDown
Affiliations

Vice President of Innovations and Evidence-Based Medicine Development, EBSCO Health; Massachusetts, United States; Clinical Research Assistant Professor, University of Missouri-Columbia

Deputy Editor
Peter Oettgen MD
KeyboardArrowDown
Affiliations

Editor in Chief, DynaMed; Cardiologist, Beth Israel Deaconess Medical Center; Massachusetts, United States; Associate Professor of Medicine, Harvard Medical School; Massachusetts, United States

Conflicts of Interest

Dr. Oettgen declares no relevant financial conflicts of interest.

CheckCircle

top